X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (38420) 38420
Publication (3357) 3357
Newsletter (648) 648
Newspaper Article (643) 643
Book Review (336) 336
Book Chapter (202) 202
Dissertation (47) 47
Book / eBook (34) 34
Conference Proceeding (34) 34
Magazine Article (32) 32
Trade Publication Article (20) 20
Web Resource (10) 10
Data Set (7) 7
Reference (6) 6
Report (2) 2
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (21732) 21732
male (16194) 16194
humans (14196) 14196
index medicus (13469) 13469
rats (10602) 10602
adenosine (10406) 10406
female (8460) 8460
adenosine triphosphate - metabolism (5551) 5551
mice (5252) 5252
pharmacology & pharmacy (4955) 4955
neurosciences (4412) 4412
middle aged (3770) 3770
cardiac & cardiovascular systems (3599) 3599
dose-response relationship, drug (3468) 3468
adult (3235) 3235
rats, sprague-dawley (3045) 3045
adenosine triphosphatase (2982) 2982
adenosine - pharmacology (2887) 2887
physiology (2881) 2881
time factors (2869) 2869
biochemistry & molecular biology (2749) 2749
research (2702) 2702
rats, wistar (2679) 2679
analysis (2596) 2596
aged (2595) 2595
adenosine triphosphate (2534) 2534
in vitro techniques (2478) 2478
physiological aspects (2467) 2467
cell biology (2355) 2355
proteins (2238) 2238
metabolism (2162) 2162
adenosine - analogs & derivatives (2077) 2077
rodents (2048) 2048
atp (2047) 2047
disease models, animal (2038) 2038
oxidative stress (1949) 1949
adenosine - administration & dosage (1912) 1912
activation (1901) 1901
ischemia (1897) 1897
inhibition (1884) 1884
apoptosis (1836) 1836
brain (1829) 1829
adenosine triphosphate - pharmacology (1791) 1791
expression (1724) 1724
inflammation (1648) 1648
article (1647) 1647
cells, cultured (1634) 1634
adenosine triphosphatases - metabolism (1588) 1588
medicine (1583) 1583
health aspects (1573) 1573
research article (1548) 1548
platelet aggregation - drug effects (1527) 1527
cells (1510) 1510
peripheral vascular disease (1462) 1462
adenosine diphosphate - pharmacology (1459) 1459
receptors (1449) 1449
rat (1441) 1441
phosphorylation (1413) 1413
dogs (1411) 1411
care and treatment (1403) 1403
kinases (1376) 1376
myocardium - metabolism (1353) 1353
gene expression (1343) 1343
heart (1334) 1334
surgery (1329) 1329
enzymes (1328) 1328
signal transduction (1325) 1325
rats, inbred strains (1319) 1319
medicine, research & experimental (1318) 1318
rabbits (1317) 1317
treatment outcome (1310) 1310
caffeine (1291) 1291
hematology (1290) 1290
mice, inbred c57bl (1280) 1280
calcium - metabolism (1268) 1268
adenosine - metabolism (1259) 1259
nitric oxide (1253) 1253
cardiology (1248) 1248
endocrinology & metabolism (1248) 1248
mitochondria (1248) 1248
multidisciplinary sciences (1247) 1247
oncology (1240) 1240
cancer (1181) 1181
kinetics (1158) 1158
liver - metabolism (1147) 1147
immunology (1142) 1142
medicine & public health (1101) 1101
blood pressure - drug effects (1086) 1086
neurons (1084) 1084
receptor (1083) 1083
studies (1083) 1083
liver (1050) 1050
science (1033) 1033
pharmacology (1026) 1026
muscle proteins (1016) 1016
nitric-oxide (1003) 1003
adenosine receptors (995) 995
brain - metabolism (987) 987
biochemistry (980) 980
neurology (980) 980
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (25) 25
Earth Sciences (Noranda) - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Online Resources - Online (1) 1
Scarborough Hospital - General (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38943) 38943
Russian (293) 293
German (177) 177
Japanese (160) 160
French (80) 80
Chinese (59) 59
Spanish (55) 55
Italian (52) 52
Polish (36) 36
Ukrainian (29) 29
Portuguese (16) 16
Korean (12) 12
Czech (9) 9
Slovak (9) 9
Hungarian (8) 8
Turkish (7) 7
Swedish (6) 6
Bulgarian (2) 2
Croatian (2) 2
Danish (2) 2
Persian (2) 2
Serbian (2) 2
Afrikaans (1) 1
Dutch (1) 1
Finnish (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article
Thrombosis Research, ISSN 0049-3848, 01/2017, Volume 149, pp. 88 - 94
Journal Article
Molecular Neurobiology, ISSN 0893-7648, 8/2018, Volume 55, Issue 8, pp. 7038 - 7048
Journal Article
European Heart Journal, ISSN 0195-668X, 2017, Volume 38, Issue 41, pp. 3070 - 3078
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 04/2003, Volume 125, Issue 15, pp. 4451 - 4459
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2011, Volume 58, Issue 22, pp. 2263 - 2269
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with... 
Cardiovascular | Internal Medicine | non–ST-segment elevation myocardial infarction | chronic kidney disease | bleeding | ST-segment elevation myocardial infarction | unstable angina | acute coronary syndrome(s) | antiplatelet | antithrombotic | nonST-segment elevation myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | WAVE MYOCARDIAL-INFARCTION | HIGH-RISK PATIENTS | GLYCOPROTEIN IIB/IIIA INHIBITORS | non-ST-segment elevation myocardial infarction | MOLECULAR-WEIGHT HEPARIN | PLATELET INHIBITION | DOUBLE-BLIND | ST-SEGMENT ELEVATION | STAGE RENAL-DISEASE | UNFRACTIONATED HEPARIN | ARTERY-DISEASE | Piperazines - administration & dosage | Prasugrel Hydrochloride | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Heparin - administration & dosage | Thiophenes - administration & dosage | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Acute Coronary Syndrome - complications | Aspirin - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Polysaccharides - administration & dosage | Kidney Diseases - complications | Platelet Aggregation Inhibitors - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Clinical Trials as Topic | Uremia - complications | Adenosine - administration & dosage | Piperazines - adverse effects | Recombinant Proteins - administration & dosage | Ticlopidine - analogs & derivatives | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Hemorrhage - chemically induced | Chronic Disease | Care and treatment | Chronic kidney failure | Cardiac patients | Cardiology | Coronary heart disease | Health aspects | Cardiovascular agents | Medical colleges | Mortality | Heart attacks | Drug therapy | Acute coronary syndromes | Coronary vessels
Journal Article
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, ISSN 0363-6119, 10/2009, Volume 297, Issue 4, pp. 1095 - 1102
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article